BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Swainsonine

An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.

300+ PubMed studies analyzed · 1 RCTs · Evidence Score: 36.4

Research Domains

Swainsonine has been studied across 20 research domains including 🔬 Oncology, 🧠 Focus & Attention, 🫘 Kidney, 🫁 Liver & Detox, 🔬 Inflammation. The primary research focus is 🔬 Oncology with 24% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Swainsonine, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

ceritinib
2 shared targets
defosbarasertib
2 shared targets
quizartinib
2 shared targets
bosutinib
2 shared targets
midostaurin
2 shared targets
Crizotinib
2 shared targets
nintedanib
2 shared targets
r
2 shared targets
fedratinib
2 shared targets
kw
2 shared targets
Loading evidence profile...

This evidence profile for Swainsonine is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.